← Back to Search

Topoisomerase I inhibitors

Lurbinectedin +/- Irinotecan for Small Cell Lung Cancer

Phase 3
Recruiting
Research Sponsored by PharmaMar
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from the date of randomization to the date of death or last contact, up to 39 months
Awards & highlights

Study Summary

This trial is testing two different experimental treatments for small cell lung cancer that has returned after one other treatment. One experimental treatment is a single drug, and the other experimental treatment is a combination of two drugs. The trial will compare how well the experimental treatments work to a standard treatment.

Who is the study for?
Adults with small-cell lung cancer who've had one prior platinum-based chemotherapy can join this trial. They must have good organ function, no recent serious heart issues or uncontrolled infections, and cannot be pregnant or breastfeeding. Participants need to agree to use effective contraception and should not have been treated with certain drugs like lurbinectedin before.Check my eligibility
What is being tested?
The LAGOON trial is testing the effectiveness of Lurbinectedin alone (Group A) or combined with Irinotecan (Group B), compared to the standard treatment choice of Topotecan or Irinotecan (Group C). This phase III study randomly assigns patients to these groups in an open-label setting.See study design
What are the potential side effects?
Possible side effects include fatigue, nausea, low blood counts leading to increased infection risk, liver enzyme changes, shortness of breath from lung inflammation, allergic reactions and potential for other drug-specific adverse effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline and every six weeks (± one week) until end of treatment, up to 39 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline and every six weeks (± one week) until end of treatment, up to 39 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall survival
Secondary outcome measures
Duration of response by IA
Duration of response by IRC
Overall response rate by IA
+10 more

Side effects data

From 2016 Phase 4 trial • 128 Patients • NCT01588990
68%
Nausea
63%
Neuropathy peripheral
63%
Fatigue
55%
Diarrhoea
40%
Constipation
31%
Abdominal pain
30%
Palmar-plantar erythrodysaesthesia syndrome
28%
Vomiting
25%
Neutropenia
24%
Mucosal inflammation
23%
Epistaxis
22%
Decreased appetite
20%
Paraesthesia
20%
Insomnia
20%
Alopecia
20%
Gastrooesophageal reflux disease
19%
Headache
18%
Hypertension
17%
Stomatitis
17%
Back pain
16%
Urinary tract infection
16%
Rash
16%
Dysgeusia
14%
Upper respiratory tract infection
14%
Pain in extremity
13%
Mouth ulceration
13%
Thrombocytopenia
13%
Arthralgia
12%
Anaemia
12%
Dysaesthesia
11%
Weight decreased
11%
Oedema peripheral
11%
Musculoskeletal pain
10%
Dyspnoea
10%
Cough
10%
Abdominal pain upper
10%
Dyspepsia
10%
Pulmonary embolism
10%
Dizziness
9%
Depression
9%
Dysphonia
9%
Pyrexia
8%
Dry skin
8%
Anxiety
8%
Fall
8%
Proteinuria
7%
Lethargy
7%
Abdominal distension
7%
Rectal haemorrhage
7%
Toothache
7%
Neck pain
6%
Oropharyngeal pain
6%
Dehydration
6%
Rhinorrhoea
6%
Non-cardiac chest pain
5%
Intestinal obstruction
5%
Hypoalbuminaemia
5%
Nail disorder
5%
Hypotension
5%
Haemorrhoids
5%
Oral candidiasis
5%
Oral herpes
5%
Hypokalaemia
5%
Muscle spasms
5%
Sepsis
2%
Gastroenteritis
2%
Bronchitis
2%
Lower respiratory tract infection
2%
Pneumonia
2%
Small intestinal obstruction
2%
Anal abscess
2%
Flank pain
2%
Renal failure acute
2%
Confusional state
2%
Febrile neutropenia
2%
Angina pectoris
2%
Enterovesical fistula
1%
Anal fissure
1%
Clostridium difficile colitis
1%
Infected dermal cyst
1%
Intestinal perforation
1%
Colonic obstruction
1%
Inguinal hernia
1%
Muscle abscess
1%
Ileus
1%
Gastroenteritis viral
1%
Colitis
1%
Gastrointestinal perforation
1%
Infective exacerbation of chronic obstructive airways disease
1%
Lobar pneumonia
1%
Pharyngitis
1%
Pneumonia streptococcal
1%
Large intestine perforation
1%
Melaena
1%
Neutropenic colitis
1%
Cholecystitis acute
1%
Urosepsis
1%
Wound infection
1%
Infusion related reaction
1%
Procedural site reaction
1%
Cerebrovascular accident
1%
Hemiparesis
1%
Syncope
1%
Rectal perforation
1%
Catheter site pain
1%
Extravasation
1%
Abscess limb
1%
Radius fracture
1%
Hypomagnesaemia
1%
Hypophagia
1%
Haematuria
1%
Hydronephrosis
1%
Urinary incontinence
1%
Pleural effusion
1%
Pleuritic pain
1%
Musculoskeletal chest pain
1%
Procedural pain
1%
Laceration
1%
Gastrointestinal haemorrhage
1%
Large intestinal obstruction
1%
Transient ischaemic attack
1%
Acute psychosis
1%
Pneumonia aspiration
1%
Jugular vein thrombosis
1%
Orthostatic hypotension
1%
Thrombophlebitis superficial
1%
Device related infection
1%
Ear infection
1%
Enterocolitis infectious
1%
Eyelid infection
1%
Gangrene
1%
Pilonidal cyst
1%
Gastritis
1%
Visual impairment
1%
Dysphagia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Bevacizumab: Phase A and Phase B

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Lurbinectedin plus IrinotecanExperimental Treatment2 Interventions
Patients will consecutively receive the following q3wk (every three weeks = one treatment cycle): Irinotecan (Day 1 and Day 8) Lurbinectedin (Day 1)
Group II: LurbinectedinExperimental Treatment1 Intervention
Patients will consecutively receive lurbinectedin on Day 1 q3wk (every three weeks = one treatment cycle)
Group III: Control armActive Control2 Interventions
Best Investigator's choice prior to randomization between: Irinotecan on Day 1 q3wk Topotecan on Days 1-5 q3wk
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Irinotecan
2017
Completed Phase 4
~2680
Lurbinectedin
2022
Completed Phase 2
~90

Find a Location

Who is running the clinical trial?

PharmaMarLead Sponsor
90 Previous Clinical Trials
10,832 Total Patients Enrolled

Media Library

Irinotecan (Topoisomerase I inhibitors) Clinical Trial Eligibility Overview. Trial Name: NCT05153239 — Phase 3
Small Cell Lung Cancer Research Study Groups: Lurbinectedin plus Irinotecan, Control arm, Lurbinectedin
Small Cell Lung Cancer Clinical Trial 2023: Irinotecan Highlights & Side Effects. Trial Name: NCT05153239 — Phase 3
Irinotecan (Topoisomerase I inhibitors) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05153239 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there other ways in which Irinotecan has been studied?

"663 clinical trials have been completed for irinotecan since 2002, when it was first studied at Mayo Clinic. As of now, there are 336 active studies being conducted, a large portion of which are based in Toronto and North carolina."

Answered by AI

Are there vacancies in this trial for new participants?

"Yes, this clinical trial is still looking for participants. The most recent update on clinicaltrials.gov was on November 3rd, 2022 and the trial was originally posted on July 22nd of the same year."

Answered by AI

What has been the most common side effect in people who have taken Irinotecan?

"There is some clinical evidence to support the efficacy of irinotecan, as well as numerous rounds of data collected to support its safety. Consequently, we have rated irinotecan as a 3 on our safety scale."

Answered by AI

At how many different hospitals is this clinical trial taking place?

"University Health Network - Princess Margaret Hospital in Toronto, North carolina, FirstHealth Outpatient Cancer Center in Pinehurst, Illinois, and McGill University Health Centre (MUHC) in Montréal, Massachusetts are all locations where this study is recruiting patients. In addition, there are 6 other sites."

Answered by AI

What conditions does Irinotecan treat most often?

"Most often, irinotecan is used to treat leukemia, myelocytic, and acute conditions. However, it has also been known to be effective in treating colorectal carcinoma, ovarian cancer, and sarcoma."

Answered by AI

Who else is applying?

What site did they apply to?
Florida Cancer Specialists - South
What portion of applicants met pre-screening criteria?
Did not meet criteria
~352 spots leftby Apr 2026